Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090464 · ClinicalTrials.gov registry record
A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 328
- Enrollment target
NCT03090464: Completed study, sponsored by AstraZeneca.
NCT03090464 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 328 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03090464 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 328 participants
- Enrollment target
Study Summary
Type 2 diabetes mellitus is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction. There is evidence that patient support in various forms can have a significant positive impact on adherence to treatment and the meeting of targets in patients with type 2 diabetes mellitus. The purpose of this study is to evaluate if the use of a digital disease management tool (Smart phone- web portal-based tool), in addition to Standard of Care for T2DM, will improve glycemic control. Other variables important in T2DM (such as weight, blood pressure, and lipid levels), will also be evaluated along with patient-reported outcomes, such as satisfaction with treatment and adherence to their antihyperglycemic treatment. Study duration is 6 months
Primary Outcome
Assessed from blood samples taken at visits per standard of care
Interventions
- OTHER Use of digital disease management tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2018-05-21 |
What the finished NCT03090464 record still lists
NCT03090464 is an observational study that tracks outcomes without assigning an intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Use of digital disease management tool is the first listed.
NCT03090464 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03090464 about?
NCT03090464 is a clinical study titled "A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM". Type 2 diabetes mellitus is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction. There is evidence that patient support in various forms can have a significant positive impact ...
What is the current status of trial NCT03090464?
This trial is currently completed. The enrollment target is 328 participants. The study started on 2017-05-08. Estimated completion is 2018-05-21.
What interventions are being tested in trial NCT03090464?
The interventions under investigation include: Use of digital disease management tool (OTHER).
Who is sponsoring clinical trial NCT03090464?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
- NCT05548413 · 328 participants · NA
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
- NCT06393725 · 328 participants · NA
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI